Effect of Salvia plebeia Extract on Patients with Solid Cancer: A Preliminary Clinical Trial Protocol
![]() |
Boram, Lee
(KM Science Research Division, Korea Institute of Oriental Medicine)
Sookjin, Pyo (East West Cancer Center, Daejeon Korean Medicine Hospital) Ae-Ran, Kim (Clinical Research Coordinating Team, Korea Institute of Oriental Medicine) Eunbin, Kwag (East West Cancer Center, Daejeon Korean Medicine Hospital) Jang-Gi, Choi (KM Application Center, Korea Institute of Oriental Medicine) Hwaseung, Yoo (East West Cancer Center, Seoul Korean Medicine Hospital, Daejeon ) Hwan-Suck, Chung (KM Application Center, Korea Institute of Oriental Medicine) Jongkwan, Jo (East West Cancer Center, Daejeon Korean Medicine Hospital) |
1 | Bang S, Quy Ha TK, Lee C, et al. Antiviral activities of compounds from aerial parts of Salvia plebeia R. Br. J Ethnopharmacol 2016; 192: 398-405 DOI |
2 | Liang YY, Wan XH, Niu FJ, et al. Salvia plebeia R. Br. : an overview about its traditional uses, chemical constituents, pharmacology and modern applications. Biomed Pharmacother 2020; 121: |
3 | Seo HW, Suh JH, Kyung JS, et al. Subacute Oral Toxicity and Bacterial Mutagenicity Study of a Mixture of Korean Red Ginseng (Panax ginseng C.A. Meyer) and Salvia plebeia R. Br. Extracts. Toxicol Res 2019; 35: 215-224. DOI |
4 | Wang J, Yan W, Xu J, et al. Research progress in chemical constituents and pharmacological effects of Salvia plebeia R. Br J Hunan Univ Chin Med 2018;38: 482-485. |
5 | Shin HJ, Gwak HM, Jang M, et al. Anti-inflammatory activity of three kinds of Salvia and its active compounds. Korean Journal of Medicinal Crop Science 2016; 24: 401-407. DOI |
6 | Jiao L, Dong C, Liu J, et al. Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients. Sci Rep 2017; 7: 46524. |
7 | Choi JG, Kim YS, Kim JH, et al. Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model. Front Immunol 2020; 11: 598556. |
8 | Kim H, Yoo HJ, Kim YJ, et al. Development and validation of Korean functional assessment cancer therapy-general (FACT-G). Korean J Clin Psychol 2003; 22: 215-229. |
9 | Huang Y-f, Xie W-j, Fan H-y, et al. Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis. Frontiers in Oncology 2019; 9. |
10 | Van Allen EM, Golay HG, Liu Y, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res 2015; 3: 855-863. DOI |
11 | Yau SH. Immunotherapy for metastatic cancer patients: the current status, limitations, obstacles and future directions. Ann Palliat Med 2020; 9: 121-125. DOI |
![]() |